- Home
- BIIB vs NRG Comparison
BIIB vs NRG Comparison
Compare BIIB & NRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- NRG
- Stock Information
- Founded
- BIIB 1978
- NRG 1989
- Country
- BIIB United States
- NRG United States
- Employees
- BIIB N/A
- NRG N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- NRG Electric Utilities: Central
- Sector
- BIIB Health Care
- NRG Utilities
- Exchange
- BIIB Nasdaq
- NRG Nasdaq
- Market Cap
- BIIB 19.9B
- NRG 19.1B
- IPO Year
- BIIB 1991
- NRG 2000
- Fundamental
- Price
- BIIB $131.32
- NRG $102.87
- Analyst Decision
- BIIB Buy
- NRG Buy
- Analyst Count
- BIIB 27
- NRG 7
- Target Price
- BIIB $220.50
- NRG $123.29
- AVG Volume (30 Days)
- BIIB 1.7M
- NRG 3.4M
- Earning Date
- BIIB 04-23-2025
- NRG 05-06-2025
- Dividend Yield
- BIIB N/A
- NRG 1.71%
- EPS Growth
- BIIB 40.28
- NRG N/A
- EPS
- BIIB 11.18
- NRG 4.99
- Revenue
- BIIB $9,675,900,000.00
- NRG $28,130,000,000.00
- Revenue This Year
- BIIB N/A
- NRG $13.34
- Revenue Next Year
- BIIB N/A
- NRG $2.07
- P/E Ratio
- BIIB $11.75
- NRG $20.61
- Revenue Growth
- BIIB N/A
- NRG N/A
- 52 Week Low
- BIIB $128.51
- NRG $65.11
- 52 Week High
- BIIB $238.00
- NRG $117.26
- Technical
- Relative Strength Index (RSI)
- BIIB 32.77
- NRG 56.56
- Support Level
- BIIB $138.65
- NRG $92.93
- Resistance Level
- BIIB $144.07
- NRG $104.20
- Average True Range (ATR)
- BIIB 3.61
- NRG 3.72
- MACD
- BIIB -1.09
- NRG 0.64
- Stochastic Oscillator
- BIIB 14.92
- NRG 89.59
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About NRG NRG Energy Inc.
NRG Energy is one of the largest retail energy providers in the us, with 6 million customers. Vivint Smart Home, which NRG acquired in 2023, has 2 million home services customers. NRG also is one of the largest us independent power producers, with 13 gigawatts of coal, gas, and oil power generation capacity primarily in Texas. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.